相似文献
1
Cobimetinib and Irinotecan Liposome.考比替尼和伊立替康脂质体
Hosp Pharm. 2016 Mar;51(3):208-211. doi: 10.1310/hpj5103-208. Epub 2016 Mar 1.
2
Drug Monographs: Trabectedin and Trifluridine-Tipiracil.药物专论：曲贝替定与曲氟尿苷-替匹嘧啶
Hosp Pharm. 2016 Feb;51(2):120-128. doi: 10.1310/hpj5102-120. Epub 2016 Feb 1.
3
Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Breast Cancer.帕妥珠单抗、曲妥珠单抗和多西他赛用于HER2阳性乳腺癌
Hosp Pharm. 2016 Jan;51(1):35-38. doi: 10.1310/hpj5101-35. Epub 2016 Jan 1.
4
Drug Monographs: Ziv-aflibercept and Vincristine Sulfate Liposome.药品说明书：阿柏西普和硫酸长春新碱脂质体。
Hosp Pharm. 2013 Jan;48(1):14-22. doi: 10.1310/hpj4801-14.
5
Irinotecan and Carboplatin (IC) Regimen for Small-Cell Lung Cancer and Non-Small-Cell Lung Cancer.伊立替康与卡铂（IC）方案用于小细胞肺癌和非小细胞肺癌
Hosp Pharm. 2014 Jul;49(7):603-11. doi: 10.1310/hpj4907-603.
6
Nivolumab and Olaparib.纳武单抗和奥拉帕利。
Hosp Pharm. 2015 May;50(5):356-66. doi: 10.1310/hpj5005-356.
7
Enzalutamide and ruxolitinib.恩杂鲁胺和芦可替尼。
Hosp Pharm. 2013 Feb;48(2):104-7. doi: 10.1310/hpj4802-104.
8
Blinatumomab and Pembrolizumab.博纳吐单抗和帕博利珠单抗。
Hosp Pharm. 2015 Apr;50(4):269-73. doi: 10.1310/hpj5004-269. Epub 2015 Apr 8.
9
Lenvatinib and Palbociclib.乐伐替尼和哌柏西利。
Hosp Pharm. 2015 Jul;50(7):578-82. doi: 10.1310/hpj5007-578. Epub 2015 Jul 31.
10
Dinutuximab and Panobinostat.地努图希单抗和帕比司他。
Hosp Pharm. 2015 Oct;50(9):767-72. doi: 10.1310/hpj5009-767. Epub 2015 Oct 14.
本文引用的文献
1
Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.实体瘤患者中可瑞达的群体药代动力学及给药影响
Cancer Chemother Pharmacol. 2015 Nov;76(5):917-24. doi: 10.1007/s00280-015-2862-0. Epub 2015 Sep 13.
2
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.纳米脂质体伊立替康（PEP02）在晚期实体瘤患者中的I期研究。
Cancer Chemother Pharmacol. 2015 Mar;75(3):579-86. doi: 10.1007/s00280-014-2671-x. Epub 2015 Jan 11.
3
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.联合维莫非尼和考比替尼治疗 BRAF 突变型黑色素瘤。
N Engl J Med. 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29.
4
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer.一项针对吉西他滨耐药转移性胰腺癌患者的纳米脂质体伊立替康蔗糖酯（PEP02，MM-398）的多中心 2 期研究。
Br J Cancer. 2013 Aug 20;109(4):920-5. doi: 10.1038/bjc.2013.408. Epub 2013 Jul 23.
5
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma.一项 PEP02（MM-398）、伊立替康或多西他赛作为局部晚期或转移性胃或胃食管连接部腺癌二线治疗的随机 II 期研究。
Ann Oncol. 2013 Jun;24(6):1567-73. doi: 10.1093/annonc/mdt002. Epub 2013 Feb 13.
6
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.MEK 抑制剂 GDC-0973 联合 PI3K 抑制剂 GDC-0941 的间歇性给药可引发强烈的细胞凋亡并抑制肿瘤生长。
Cancer Res. 2012 Jan 1;72(1):210-9. doi: 10.1158/0008-5472.CAN-11-1515. Epub 2011 Nov 14.
Zotero 插件